Australia Shares Low-dose Ivermectin Therapy Protocol for Bs-19
By BioSpectrum Asia
Australian triple therapy specialist Professor Thomas Borody, internationally famous for curing peptic ulcers using a triple antibiotic therapy saving thousands of lives, said 34 prescriptions for the inexpensive low-dose Ivermectin Triple Therapy 10-day treatment protocol have been written by GPs.
There have been numerous requests for the protocol via the GP@CDD.com.au including 57 Australian GPs, 30 doctors from overseas, and enquires from 184 members of the public (the protocol is only available to verified GPs as a prescription-only).
The Ivermectin triple therapy seems to be the cheapest, safest, and rapidly-curing treatment for Australians, and used broadly could stimulate the Australian economy. Professor Borody says his research has led him to a triple therapy of Ivermectin, zinc and an antibiotic – which are all TGA and FDA approved.
In-fact more than 60% of prescriptions in Australia are “off-label”. It’s not a new concept. It’s happening legally every day to manage diseases and save lives.”
Professor Borody, an internationally regarded physician with 4 FDA approved drugs, is famous for developing the triple therapy that cured patients with peptic ulcers saving more than 18,000 lives in Australia alone and millions internationally.
“No trial has shown Ivermectin-based therapy to be ineffective. In-fact, international trials report almost 100% cure rate with symptom improvement within 4-6 days. This needs to be available for aged care facilities and frontline health workers today.” he said.
We have written to the Federal Health Minister Greg Hunt and Victorian Premier Daniel Andrews for an urgent medical briefing to bypass the raft of “advisors” who failed to understand TGA-approved medicines do not require animal studies.
The therapy comprises: Ivermectin – TGA and FDA approved as an anti-parasitic therapy with an established safety profile since the 1970s. Known as the “Wonder Drug” from Japan; Zinc and Doxycycline – TGA and FDA approved tetracycline antibiotic that fights bacterial infections, eg acne or urinary tract infections, viral and malarial.
Professor Borody is involved in a Phase 2 study in the US to potentially develop the triple therapy as a single “blister pack” compliance product and is awaiting FDA approval.